Format

Send to

Choose Destination
Trends Cardiovasc Med. 2019 Feb 20. pii: S1050-1738(19)30025-8. doi: 10.1016/j.tcm.2019.02.007. [Epub ahead of print]

Recent paradigm shifts in molecular cardiac imaging-Establishing precision cardiology through novel 18F-labeled PET radiotracers.

Author information

1
Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States; Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany; Comprehensive Heart Failure Center, University Hospital Wuerzburg, Wuerzburg, Germany. Electronic address: werner_r1@ukw.de.
2
Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany; Comprehensive Heart Failure Center, University Hospital Wuerzburg, Wuerzburg, Germany.
3
Division of Nuclear Medicine and Molecular Imaging, The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
4
Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany.
5
Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany; Comprehensive Heart Failure Center, University Hospital Wuerzburg, Wuerzburg, Germany; Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. Electronic address: thiguchi@me.com.

Abstract

In nuclear cardiology, numerous single-photon emission computed tomography radiotracers have been advocated to reflect various cardiac metabolic and functional conditions, but positron emission tomography (PET) may offer a more thorough evaluation, mainly due to superior characteristics associated with the latter imaging modality. This shift in recent years has been fueled by the introduction of 18F-labeled PET radiotracers. Due to physical and chemical key properties, these imaging agents allow for more flexibility of imaging protocols and a better employment in the clinic. Potentially rendering perfusion, viability, innervation and inflammation, 18F-labeled PET radiotracers may truly pave the way for a global assessment of the current metabolic and functional status of the heart, e.g. after acute myocardial infarction or for progressed heart failure. The present review aims to provide a precise overview of those recently introduced 18F-labeled cardiac imaging agents and how those state-of-the-art, top-tier radiotracers may redefine precision medicine in cardiology.

KEYWORDS:

(18)F; Heart failure; Inflammation; Innervation; MPI; Myocardial infarction; Myocardial perfusion imaging; PET; Positron emission tomography; SPECT; Single-photon emission computed tomography; Viability

PMID:
30824163
DOI:
10.1016/j.tcm.2019.02.007
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center